CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4 enrolled
Drug / intervention
Ipilimumab at 3 mg/kg dosedrug
Likely dose
Ipilimumab at 3 mg/kg dosefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01715077
NCT01715077N/ACompleted
CompareCT.gov

A Correlative Study of Melanoma Tumor-Infiltrating Lymphocytes (TILs) and Response to Ipilimumab

University Health Network, Toronto·interventional·Posted Oct 26, 2012·Updated Aug 13, 2018

In Brief

A clinical study evaluating Ipilimumab at 3 mg/kg dose for Previously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma. Completed, enrolled 4 participants across 1 site.

Detailed Summary

Participants will be taking 3 mg/kg ipilimumab intravenously over a 90-minute period every 3 weeks for a total of four doses. Tumor-infiltrating lymphocytes (TILs)will be analyzed for functional characteristics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPreviously Untreated and Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 26, 2012
Enrollment StartOct 1, 2012
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 13.7 years ago

Interventions

Ipilimumab at 3 mg/kg dosedrug